Big pharma

#Antibody drug conjugate (ADC) #Big pharma #Drug development #Drug discovery #Heidelberg Pharma #Takeda #Therapeutic Antibodies

A global overview of therapeutic antibody development

DDW’s Megan Thomas takes a wide-angle look at the sector and speaks to experts and thought leaders about their predictions for therapeutic antibodies in 2025. Clinical advancements Marcelo Freire, Vice President of Global Medical Affairs, Therapeutic Area Head of Gastroenterology at Takeda, comments on monoclonal antibodies (mAbs) from a gastro… Read More

#Business & Investment #Exclusive Content

Magnifying glass
#Big pharma #Novo Nordisk #Pharmaceuticals #University of Bath

Critics say pharma giant has “deep cultural issues”

The UK’s Channel 4’s Dispatches: Skinny Jab Scandal investigational documentary has highlighted significant concerns about pharmaceutical giant Novo Nordisk’s promotional practices. Here, DDW outlines the case and provides comment from a Novo Nordisk spokesperson. The documentary featured expert insights from Dr Piotr Ozieranski and Dr Emily Rickard of the University… Read More

#Business & Investment #News

World Health Organization
#Big pharma #Drug development #Opinion #Politics #World Health Organization

How will a Trump withdrawal from the WHO impact drug development?

In one of his first acts as President, Donald Trump signed an executive order to withdraw the US from the World Health Organization (WHO). DDW’s Megan Thomas spoke with three industry leaders to understand the impact this will have on the drug development sector. Cell and gene therapy According… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory

#Big pharma #Funding #Patient groups #Pharmaceutical industry #University of Bath

Patient groups influenced by drug company funding, study finds

Action is needed to safeguard the independence of patient organisations and charities, according to the findings of a new study.  The study by the University of Bath, UK, Lund University, Sweden and Kozminski University, Poland, concludes that patient organisations and charities across Europe are at risk of… Read More

#Business & Investment #News

Judge's gavel
#Association of the British Pharmaceutical Industry #Big pharma #Pharmaceutical industry

Novartis, Pfizer, Otsuka and Novo breach the ABPI Code

The Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Novartis, Pfizer, Otsuka and Novo Nordisk have breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. The companies were judged to have “brought discredit upon”, and “reduced confidence in”, the pharmaceutical industry. Read More

#News

#AI / data analytics / healthtech / informatics #Big pharma #BioNTech #Biopharmaceuticals #Comirnaty #Covid-19 #Drug discovery #Healthcare #Moderna #mRNA #Pfizer

New podcast on drug discovery trends

This is the latest episode of the free DDW narrated podcast, “Drug discovery trends: From regulation to embracing AI”, which covers two articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: From the Editor: Law and order and… Read More

#News

#ABPI #Big pharma #Biopharma #Covid-19 #Ipsos #UK

Pharma maintains high level of trust from UK public and doctors

The pharmaceutical industry continues to maintain strong levels of public trust and favourability in the UK, according to data from the Association of the British Pharmaceutical Industry (ABPI). Opinions showed consistent recognition of the sector’s support for the NHS, with 67% of respondents saying the industry… Read More

#News

Antibody drug conjugate
#AI / data analytics / healthtech / informatics #Antibodies #Antibody drug conjugate (ADC) #Big pharma #Drug development #Precision medicine

A personal view on antibody drug development

Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer. Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated,… Read More

#Exclusive Content

#Appointment #Big pharma #Drug discovery #Life sciences #New appointment #Pharmaceutical industry

February’s key industry appointments

There have been a number of significant appointments in the drug discovery sector over the last month. So who are the latest movers and shakers?  Amy Berrington and Montserrat Garcia-Closas, Institute of Cancer Research: Professors Amy Berrington and Montserrat Garcia-Closas have been appointed as Team Leaders at… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Big pharma #Drug development #Drug discovery #GlobalData

AI and big data will continue to disrupt pharmaceutical sector, says research

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey… Read More

#Market Reports #News #Trending News #Trends & Analysis

#Big pharma #Biotechnology #Pharmaceuticals

Sygnature Discovery expands US presence to Bay Area biotech hub

Sygnature Discovery, an integrated discovery and pre-clinical solutions provider, has a new office in South San Francisco’s biotech hub at Oyster Point, where it says it can better serve current and future clients on the US west coast. The company has grown in the previous year, having recently expanded… Read More

#News

#AI / data analytics / healthtech / informatics #Big pharma #Biopharma #Biotechnology #Covid-19 #Drug development #Drug discovery

Waters CEO explains how analytical technologies can assist drug discovery

Udit Batra, CEO of Waters, is known as a listener, learner and gatherer of facts. He talks to Lu Rahman about Waters’ collaboration with pharma and biopharma companies to accelerate vaccine and therapy development as well as the company’s new data analysis technology. LR: We know that the last year… Read More

#Exclusive Content #News